Safety and Efficacy Study of rEV131 in the Treatment of Ocular Inflammation After Cataract Surgery

Status unconfirmed · Phase 2

Conditions studied: Ocular Inflammation

In brief

The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.

Key facts

Study ID

NCT00353964

Run by

Evolutec Group

Last updated by the study team

2006-07-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens

You may not qualify if…

• have unstable glaucoma
• have an active bacterial and/or viral infection
• use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.

Where it is running

• ORA Study Sites — North Andover, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.